Management of Abnormal Vaginal Cytology and HPV Tests

Author: Erin L. Nelson, MD
Mentor: Michelle Khan, MD
Editors: ASCCP Practice Committee

Vaginal cytology and/or high-risk human papillomavirus (hrHPV) testing after total hysterectomy for benign disease is not recommended, except when the patient has a history of high-grade cervical dysplasia within the past 25 years. However, these tests are often performed without a valid indication. Practitioners are then challenged with how best to manage abnormal results.

Vaginal cancer is a rare, HPV-related gynecologic malignancy with a reported incidence rate of 0.4–0.6 per 100,000 women. Cytologic abnormalities and HPV infection are both relatively common in individuals who have undergone hysterectomy. HPV infection of the vagina is found with similar frequency as HPV infection of the cervix and the prevalence of hrHPV is similar between individuals with and without hysterectomy.

Since vaginal cancer is so rare and the accuracy of vaginal hrHPV testing and cytology to predict histologic HSIL/VaIN2/3 is not very well defined in the literature, a conservative approach to management of abnormal vaginal tests is recommended.

Healthy asymptomatic individuals with negative hrHPV testing and a negative cytology are at extremely low risk and do not require future testing if they have had hysterectomy for benign disease and have no history of cervical precancer or cancer.

Individuals with a history of cervical precancer should be followed with surveillance tests for at least 25 years after their treatment as per ASCCP management guidelines. Individuals with a history of cervical cancer should be followed with surveillance tests as per NCCN guidelines.

For individuals with ASCUS, cytologic LSIL, or NILM hrHPV+ results, vaginal cotest or repeat cytology in one year is recommended (see figure 1).

In individuals with ASC-H, HSIL or AGC cytology results, vaginal colposcopy with biopsy of any lesions is recommended (see figure 1).
FIGURE 1

For individuals with persistent cytologic LSIL (beyond 2 years without progression to cytologic HSIL) consider extending the screening and colposcopy intervals to every 2-3 years. There are people (immunosuppressed or otherwise) who are not able to eradicate HPV and remain at risk.

If the biopsy result is HSIL/VaIN2/3, treatment based on current best practice is recommended. This could potentially include laser ablation, topical treatment, or excision with referral to gynecologic oncology for large or complex lesions. A biopsy result of invasive carcinoma warrants referral to gynecologic oncology.

Further reading: